ArticleBlood transfusion = Trasfusione del sangue
Clinical impact of Amotosalen and UV-A treatment (INTERCEPT™ Blood System) for platelet concentrate preparation in cardiac surgery.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnsuring transfusion safety remains a major challenge. Pathogen-reduction technologies (PRT), such as the INTERCEPT™ Blood System (IBS), use amotosalen (a psoralen) as intercalating agent in nucleic acids and ultraviolet A (UV-A) light to block pathogen replication, reducing the risk of transfusion-transmitted infections. While IBS is approved for platelet concentrate (PC) treatment, its clinical impact on platelet function remains debated. In November 2017, IBS was implemented across all French blood banks (Établissement Français du Sang, EFS) for PCs. MATERIALS AND
methodsWe conducted a retrospective "before-after" study to evaluate the impact of PRT on platelet transfusion and clinical bleeding in cardiac surgery. The pre-PRT period was from January 2016 to June 2017, and the post-PRT period from January 2018 to June 2019. The study included adult patients who received PCs during or within two days after cardiac surgery in two teaching hospitals (Nancy and Reims). Patients with heart transplantation or requiring mechanical circulatory support were excluded.
resultsA total of 357 (Nancy) and 314 (Reims) patients were included, with no changes in anticoagulation, antiplatelet therapy, or surgical procedures. Platelet transfusion amount significantly decreased post-PRT (from 0.64 [0.54-0.81] to 0.57 [0.49-0.75] ×10 DISCUSSION: The implementation of PRT using IBS did not impair the hemostatic properties of transfused platelets during cardiac surgery. Platelet and other blood product use, as well as clinical outcomes, were similar before and after PRT introduction. IBS-treated PCs are thus comparable to standard PCs in managing bleeding in cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.